Miriam Paramore is the founder and CEO of RxUtility, a company focused on helping people save money on medicine.
“I'm the founder and CEO of RxUtility, and I'm not famous.”
Person
Miriam Paramore is the founder and CEO of RxUtility, a company that helps people save money on medicine, and she appeared on Becker's Healthcare Podcast to discuss drug costs, pharmacy benefit managers and patient access. She also described her sister's breast cancer treatment, saying that on the morning of the mastectomy, check-in staff told her sister that Cigna had denied coverage for the anesthesiologist.
Paramore said there are now more price points for the same drug than ever before. She said Eliquis's list price was $600 for patients paying out of pocket in the deductible phase before direct-to-consumer sales, and is now $349 direct, or about $249 from a Canadian pharmacy. She said RxUtility aims to be the "Expedia for drug prices."
1 episodes · 10 quoted claims
Miriam Paramore is the founder and CEO of RxUtility, a company focused on helping people save money on medicine.
“I'm the founder and CEO of RxUtility, and I'm not famous.”
Miriam Paramore's sister was diagnosed with breast cancer about two years before the recording and had a double mastectomy.
“My sister was diagnosed with breast cancer two years ago, had a double mastectomy.”
According to Paramore, on the morning of her sister's mastectomy, check-in staff told the sister that Cigna had denied coverage for her anesthesiologist.
“And they said, Cigna has denied your anesthesiologist.”
Paramore says there are now more price points for the same drug than ever before, including a direct-to-patient manufacturer channel that did not exist until last year.
“we have more price points for the same drug than we've ever had before.”
Paramore says payers, pharmacy benefit managers and employers pay based on net price, while patients in a deductible phase may pay the higher list price.
“the payers, the PBMs and the employers, they all pay off of net.”
Paramore credits GoodRx with shifting the industry by arguing people should know what drugs cost, and says its business began about 12 years before the recording.
“GoodRx made a great shift in our industry when they said, we think people should know what drugs cost”
Paramore says the PBM reform policy would include TrumpRx prices in real-time pharmacy benefit checks, though she notes TrumpRx lacks some drugs and is not always cheapest.
“And the other thing is they're saying we should include the Trump Rx prices in the real-time pharmacy benefit check return.”
Paramore says Eliquis's list price for patients paying out of pocket in the deductible phase was $600 before direct-to-consumer sales.
“list price that patients are paying out of their own pocket when they're in their deductible phase for Eliquis was $600.”
Paramore says Eliquis's direct-to-consumer price is now $349, and about $249 from a Canadian pharmacy.
“$349. And do you know if you get it from a Canadian pharmacy, it's $249.”
Paramore says RxUtility aims to be the 'Expedia for drug prices', surfacing all prices so they flow through existing workflows.
“We are hoping to be the Expedia for drug prices, Scott.”